247 related articles for article (PubMed ID: 29743369)
21. Incorporation of Ebola glycoprotein into HIV particles facilitates dendritic cell and macrophage targeting and enhances HIV-specific immune responses.
Ao Z; Wang L; Mendoza EJ; Cheng K; Zhu W; Cohen EA; Fowke K; Qiu X; Kobinger G; Yao X
PLoS One; 2019; 14(5):e0216949. PubMed ID: 31100082
[TBL] [Abstract][Full Text] [Related]
22. Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus.
van Diepen MT; Chapman R; Douglass N; Galant S; Moore PL; Margolin E; Ximba P; Morris L; Rybicki EP; Williamson AL
J Virol; 2019 Apr; 93(8):. PubMed ID: 30760570
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen.
Leung L; Srivastava IK; Kan E; Legg H; Sun Y; Greer C; Montefiori DC; zur Megede J; Barnett SW
AIDS; 2004 Apr; 18(7):991-1001. PubMed ID: 15096801
[TBL] [Abstract][Full Text] [Related]
24. CD4
Klessing S; Temchura V; Tannig P; Peter AS; Christensen D; Lang R; Überla K
Vaccines (Basel); 2020 Oct; 8(4):. PubMed ID: 33066267
[TBL] [Abstract][Full Text] [Related]
25. Impact of T
Verma A; Schmidt BA; Elizaldi SR; Nguyen NK; Walter KA; Beck Z; Trinh HV; Dinasarapu AR; Lakshmanappa YS; Rane NN; Matyas GR; Rao M; Shen X; Tomaras GD; LaBranche CC; Reimann KA; Foehl DH; Gach JS; Forthal DN; Kozlowski PA; Amara RR; Iyer SS
J Virol; 2020 Feb; 94(6):. PubMed ID: 31827000
[TBL] [Abstract][Full Text] [Related]
26. Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses.
Zurawski G; Shen X; Zurawski S; Tomaras GD; Montefiori DC; Roederer M; Ferrari G; Lacabaratz C; Klucar P; Wang Z; Foulds KE; Kao SF; Yu X; Sato A; Yates NL; LaBranche C; Stanfield-Oakley S; Kibler K; Jacobs B; Salazar A; Self S; Fulp W; Gottardo R; Galmin L; Weiss D; Cristillo A; Pantaleo G; Levy Y
J Virol; 2017 May; 91(9):. PubMed ID: 28202751
[TBL] [Abstract][Full Text] [Related]
27. Divergence of primary cognate B- and T-cell proliferative responses to subcutaneous and intravenous immunization with virus-like particles.
Temchura V; Kalinin S; Nabi G; Tippler B; Niezold T; Uberla K
Viruses; 2014 Aug; 6(8):3334-47. PubMed ID: 25153345
[TBL] [Abstract][Full Text] [Related]
28. HIV-1 virus-like particles produced by stably transfected Drosophila S2 cells: a desirable vaccine component.
Yang L; Song Y; Li X; Huang X; Liu J; Ding H; Zhu P; Zhou P
J Virol; 2012 Jul; 86(14):7662-76. PubMed ID: 22553333
[TBL] [Abstract][Full Text] [Related]
29. IL-33 enhances the kinetics and quality of the antibody response to a DNA and protein-based HIV-1 Env vaccine.
Sarkar S; Piepenbrink MS; Basu M; Thakar J; Keefer MC; Hessell AJ; Haigwood NL; Kobie JJ
Vaccine; 2019 Apr; 37(17):2322-2330. PubMed ID: 30926296
[TBL] [Abstract][Full Text] [Related]
30. HIV Env-Specific IgG Antibodies Induced by Vaccination of Neonatal Rhesus Macaques Persist and Can Be Augmented by a Late Booster Immunization in Infancy.
Curtis AD; Dennis M; Eudailey J; Walter KL; Cronin K; Alam SM; Choudhary N; Tuck RH; Hudgens M; Kozlowski PA; Pollara J; Ferrari G; Van Rompay KKA; Permar S; De Paris K
mSphere; 2020 Mar; 5(2):. PubMed ID: 32213623
[TBL] [Abstract][Full Text] [Related]
31. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
[TBL] [Abstract][Full Text] [Related]
32. Modulating the quantity of HIV Env-specific CD4 T cell help promotes rare B cell responses in germinal centers.
Lee JH; Hu JK; Georgeson E; Nakao C; Groschel B; Dileepan T; Jenkins MK; Seumois G; Vijayanand P; Schief WR; Crotty S
J Exp Med; 2021 Feb; 218(2):. PubMed ID: 33355623
[TBL] [Abstract][Full Text] [Related]
33. Similar T-cell immune responses induced by group M consensus env immunogens with wild-type or minimum consensus variable regions.
Weaver EA; Camacho ZT; Gao F
AIDS Res Hum Retroviruses; 2010 May; 26(5):577-84. PubMed ID: 20438382
[TBL] [Abstract][Full Text] [Related]
34. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
[TBL] [Abstract][Full Text] [Related]
35. Virus-like vaccines against HIV/SIV synergize with a subdominant antigen T cell vaccine.
Schwerdtfeger M; Andersson AC; Neukirch L; Holst PJ
J Transl Med; 2019 May; 17(1):175. PubMed ID: 31126293
[TBL] [Abstract][Full Text] [Related]
36. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
J Virol; 2017 May; 91(9):. PubMed ID: 28179536
[TBL] [Abstract][Full Text] [Related]
37. Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses.
Perdiguero B; Gómez CE; García-Arriaza J; Sánchez-Corzo C; Sorzano CÓS; Wilmschen S; von Laer D; Asbach B; Schmalzl C; Peterhoff D; Ding S; Wagner R; Kimpel J; Levy Y; Pantaleo G; Esteban M
Front Immunol; 2019; 10():2941. PubMed ID: 31921191
[TBL] [Abstract][Full Text] [Related]
38. Abrogation of contaminating RNA activity in HIV-1 Gag VLPs.
Valley-Omar Z; Meyers AE; Shephard EG; Williamson AL; Rybicki EP
Virol J; 2011 Oct; 8():462. PubMed ID: 21975161
[TBL] [Abstract][Full Text] [Related]
39. Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers.
Bontjer I; Melchers M; Tong T; van Montfort T; Eggink D; Montefiori D; Olson WC; Moore JP; Binley JM; Berkhout B; Sanders RW
PLoS One; 2013; 8(6):e67484. PubMed ID: 23840716
[TBL] [Abstract][Full Text] [Related]
40. Induction of tier-2 neutralizing antibodies in mice with a DNA-encoded HIV envelope native like trimer.
Xu Z; Walker S; Wise MC; Chokkalingam N; Purwar M; Moore A; Tello-Ruiz E; Wu Y; Majumdar S; Konrath KM; Kulkarni A; Tursi NJ; Zaidi FI; Reuschel EL; Patel I; Obeirne A; Du J; Schultheis K; Gites L; Smith T; Mendoza J; Broderick KE; Humeau L; Pallesen J; Weiner DB; Kulp DW
Nat Commun; 2022 Feb; 13(1):695. PubMed ID: 35121758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
